The Biostatistics Core is designed to (i) provide a wide array of diverse biostatistical methods and approaches to CFAR investigators, (ii) educate CFAR investigators in the proper use of these technologies, and (iii) conduct cutting edge methodological research germane to the field. In the budget period, the Biostatistics Core has supported 45 independently funded HIV research projects, contributed to over 100 manuscripts, abstracts and presentations, generating over $250,000 of user chargebacks.
The Specific Aims of the Biostatistics Core are: 1. To provide general statistical services including those involving study design, power analysis, data analysis, consultation on interpretation of results and aid investigators in writing up their results. 2. To develop and manage AIDS-related research databases for CFAR investigators and assist in utilizing these databases to address research questions. 3. To provide training to CFAR investigators in the areas of research design and analysis, epidemiologic methods and bioinformatics. 4. To synergize with CFAR programmatic areas and other Cores to interweave the Biostatistics Core services into those areas, and to utilize the scientific expertise of the Core to meet programmatic aims. 5. To interact across CFARs nationwide to facilitate interchange of research ideas to foster new directions The 'Value added"""""""" contributions of the Biostatistics Core to the CFAR Mission are the availability of resources and expertise in the design and analysis of studies ranging from basic science to comparative clinical trials. The CFAR Biostatistics Core is essential to provide access to expertise necessary for the special challenges to research in the prevention, treatment and evaluation of risk factors for HIV/AIDS.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027767-25
Application #
8495867
Study Section
Special Emphasis Panel (ZAI1-SV-A)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
25
Fiscal Year
2013
Total Cost
$162,496
Indirect Cost
$51,577
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Merlin, Jessica S; Long, Dustin; Becker, William C et al. (2018) Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes. J Acquir Immune Defic Syndr 79:77-82
Hamilton, Jennie A; Wu, Qi; Yang, PingAr et al. (2018) Cutting Edge: Intracellular IFN-? and Distinct Type I IFN Expression Patterns in Circulating Systemic Lupus Erythematosus B Cells. J Immunol 201:2203-2208
Stafman, Laura L; Mruthyunjayappa, Smitha; Waters, Alicia M et al. (2018) Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma. Oncotarget 9:22665-22679
Yang, Zhenhua; Shah, Kushani; Busby, Theodore et al. (2018) Hijacking a key chromatin modulator creates epigenetic vulnerability for MYC-driven cancer. J Clin Invest 128:3605-3618
Nag, Mukta; De Paris, Kristina; E Fogle, Jonathan (2018) Epigenetic Modulation of CD8? T Cell Function in Lentivirus Infections: A Review. Viruses 10:
Barr, Fiona D; Ochsenbauer, Christina; Wira, Charles R et al. (2018) Neutrophil extracellular traps prevent HIV infection in the female genital tract. Mucosal Immunol 11:1420-1428
Holdbrooks, Andrew T; Britain, Colleen M; Bellis, Susan L (2018) ST6Gal-I sialyltransferase promotes tumor necrosis factor (TNF)-mediated cancer cell survival via sialylation of the TNF receptor 1 (TNFR1) death receptor. J Biol Chem 293:1610-1622
Williams, Adele P; Waters, Alicia M; Stewart, Jerry E et al. (2018) A novel retinoid X receptor agonist, UAB30, inhibits rhabdomyosarcoma cells in vitro. J Surg Res 228:54-62
Dixit, Saurabh; Sahu, Rajnish; Verma, Richa et al. (2018) Caveolin-mediated endocytosis of the Chlamydia M278 outer membrane peptide encapsulated in poly(lactic acid)-Poly(ethylene glycol) nanoparticles by mouse primary dendritic cells enhances specific immune effectors mediated by MHC class II and CD4+ T cells. Biomaterials 159:130-145
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372

Showing the most recent 10 out of 955 publications